Substance misuse in patients with schizophrenia: epidemiology and management

Drugs
D J KavanaghDianne Clark

Abstract

Substance misuse in individuals with schizophrenia is very common, especially in young men, in communities where use is frequent and in people receiving inpatient treatment. Problematic use occurs at very low intake levels, so that most affected people are not physically dependent (with the exception of nicotine). People with schizophrenia and substance misuse have poorer symptomatic and functional outcomes than those with schizophrenia alone. Unless there is routine screening, substance misuse is often missed in assessments. Service systems tend to be separated, with poor inter-communication, and affected patients are often excluded from services because of their comorbidity. However, effective management of these disorders requires a fully integrated approach because of the close inter-relationship of the disorders. Use of atypical antipsychotics may be especially important in this population because of growing evidence (especially on clozapine and risperidone) that nicotine smoking, alcohol misuse and possibly some other substance misuse is reduced. Several pharmacotherapies for substance misuse can be used safely in people with schizophrenia, but the evidence base is small and guidelines for their use are necessarily derive...Continue Reading

References

Jul 1, 1978·Archives of General Psychiatry·K VerebeyD Clouet
Mar 1, 1992·Comprehensive Psychiatry·L DixonA J Frances
Dec 1, 1992·Schizophrenia Research·J B Lohr, K Flynn
Jan 1, 1992·Acta Psychiatrica Scandinavica. Supplementum·H Enghusen PoulsenM Andersen
Jul 1, 1989·The Journal of Nervous and Mental Disease·R E DrakeM A Wallach
Jan 1, 1982·Annals of the New York Academy of Sciences·G J McKenna
Sep 1, 1995·American Journal of Respiratory and Critical Care Medicine·M I PolkeyJ Moxham
Dec 1, 1993·Schizophrenia Research·A ZaretskyX Fornazzari
Mar 1, 1994·Hospital & Community Psychiatry·D M ZiedonisR J Frances
Jun 1, 1994·Journal of Clinical Psychopharmacology·L M BrennerJ H Krystal
Jun 1, 1997·The American Journal of Psychiatry·M F GreenJ Mintz
Nov 5, 1997·Psychiatric Services : a Journal of the American Psychiatric Association·L ApplebyL S Cohen
Jun 9, 1998·Journal of Clinical Psychopharmacology·M J SernyakL H Price
Apr 6, 1999·Schizophrenia Research·D E Casey
Jul 8, 1999·Biological Psychiatry·J P McEvoyW H Wilson
Oct 7, 2000·Journal of Studies on Alcohol·S DaweD Kavanagh
Feb 24, 2001·Hospital Medicine·C Steele
Jun 29, 2001·Archives of General Psychiatry·D LichtermannJ Lönnqvist

❮ Previous
Next ❯

Citations

Jan 2, 2007·Neurotoxicity Research·John H KrystalGodfrey Pearlson
May 22, 2007·Neurotoxicity Research·Tomas PalomoRichard J Beninger
Mar 3, 2005·Social Psychiatry and Psychiatric Epidemiology·Jyrki KorkeilaHasse Karlsson
Oct 26, 2005·Social Psychiatry and Psychiatric Epidemiology·Michael T ComptonNadine J Kaslow
Nov 25, 2003·Psychopharmacology·Ismene L PetrakisUNKNOWN VA Naltrexone Study Collaboration Group
Jun 25, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Anne-Noël Samaha
Dec 12, 2007·Psychological Medicine·P A RingenO A Andreassen
Nov 7, 2007·Neuropsychology·Cherie L MarvelNancy C Andreasen
Feb 18, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Anne-Marie BédardAnne-Noël Samaha
Sep 5, 2003·The New England Journal of Medicine·Jordi Camí, Magí Farré
Sep 11, 2007·The Australian and New Zealand Journal of Psychiatry·Stéphane PotvinEmmanuel Stip
Apr 15, 2010·Substance Abuse : Official Publication of the Association for Medical Education and Research in Substance Abuse·Sahoo SaddichhaChristoday Raja Jayant Khess
Jul 16, 2008·Cognitive Neuropsychiatry·Stéphane PotvinEmmanuel Stip
Jan 29, 2011·Primary Care Companion to the Journal of Clinical Psychiatry·Sahoo SaddichhaChristoday R J Khess
May 20, 2014·Psychiatry Journal·Rudraprosad ChakrabortySuprakash Chaudhury
Jul 26, 2013·Schizophrenia Bulletin·Amber L BahorikShaun M Eack
Jan 12, 2005·Journal of Clinical Psychopharmacology·David B MerrillDonald C Goff
Jun 30, 2005·Journal of Psychiatric Practice·Avram H Mack, Richard J Frances
Jan 14, 2004·The Journal of Nervous and Mental Disease·Cheryl EngerAlexander M Walker
Mar 15, 2006·The Journal of Nervous and Mental Disease·Marvin S SwartzJeffrey A Lieberman
Dec 5, 2015·Expert Opinion on Pharmacotherapy·Jean-Michel AzorinRaoul Belzeaux
Jul 13, 2006·Current Medical Research and Opinion·Stéphane PotvinAlain Gendron
Dec 29, 2007·The American Journal of Drug and Alcohol Abuse·Stéphane PotvinAlain Gendron
Jan 30, 2013·Journal of Substance Abuse Treatment·Yolanda AlvarezMagí Farré
Nov 6, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Irina BenaigesAna Adan
Sep 10, 2010·Schizophrenia Research·José Manuel Rodríguez-SánchezBenedicto Crespo-Facorro
Oct 27, 2009·Schizophrenia Research·Roberto Rodriguez-JimenezUNKNOWN PARG
Mar 16, 2007·Acta Psychiatrica Scandinavica·J Addington, D Addington
Sep 15, 2006·Schizophrenia Research·Tor K LarsenThomas H McGlashan
Sep 26, 2006·Addictive Behaviors·Asa ErikssonSheilagh Hodgins
Aug 2, 2005·Schizophrenia Research·W Wolfgang FleischhackerUNKNOWN EUFEST Steering Committee
Jun 2, 2011·Progress in Neuro-psychopharmacology & Biological Psychiatry·Raouf IgueEdouard Kouassi
Mar 23, 2013·Schizophrenia Research·Albert BatallaMiguel Bernardo
Aug 21, 2013·Journal of Psychiatric Research·Zuoxu FanRenya Zhan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here